Clara Campàs-Moya holds a PhD in Pharmacy by the Universitat de Barcelona. She recently joined Kern Pharma SL as Strategy & Development Director were she coordinates the following departments: R&D, innovation, business development and regulatory affairs. Formerly, she worked at Advancell, SA as Managing Director and Drug development Director, as well as a Researcher at Hospital del Mar. She is the co-author of the patent Acadesine, the first drug originated in a Spanish public University that successfully reached clinical trials. She is member of the scientific committee of the venture capital fund HealthEquity, VicePresident of CataloniaBIO and member of the board of trustees of Biocat, as well as member of the scientific committee of the MIHealth Forum.